

Special Issue

Molecular Mechanisms and Novel Therapies for Brain Injury

Message from the Guest Editor

Brain injury—whether that be stroke, spinal cord injury, traumatic brain injury, seizure, brain tumors—is the leading cause of death and disability globally. To date, numerous efforts have been made to develop new therapeutics that modulate the pathogenesis of brain injury. Unfortunately, these studies have not led to the successful development and discovery of new drug targets, biomarkers, and therapeutics that tackle brain injury. Therefore, uncovering the molecular mechanisms of injury, recovery, and neuroprotection is important for the development of novel, effective therapies. This Special Issue aims to collect up-to-date overviews of the current understandings of brain injury, molecular mechanisms, and novel therapies, as well as the possible clinical translations and therapeutic strategies to treat brain injury. These should highlight, but are not limited to, molecular or genetic manipulation affecting protective or detrimental outcomes, the mechanisms of action of various pharmacological agents, innovative therapeutic strategies for treatment, and neuroinflammation.

Guest Editor

Dr. Arjun Sapkota

Neuroscience Lab, San Diego Biomedical Research Institute, San Diego, CA, 92121, USA

Deadline for manuscript submissions

closed (30 June 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157553

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).